Inhibitors of de novo nucleotide biosynthesis as drugs

Accounts of Chemical Research

Volumn 35, Issue 11, 2002, Pages 961-971

  Christopherson, Richard I ^a   Lyons, Stephen D ^a   Wilson, Paul K ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYL 4 IMIDAZOLECARBOXAMIDE 1 RIBOSIDE; 6 METHYLTHIOINOSINE; AG 2009; AMIDOPHOSPHORIBOSYLTRANSFERASE; ATOVAQUONE; BW 566C; ENZYME INHIBITOR; FOLIC ACID ANTAGONIST; FURAN DERIVATIVE; INOSINATE DEHYDROGENASE; LEFLUNOMIDE; LOMETREXOL; LY 222306; LY 254155; MERCAPTOPURINE; MERIMEPODIB; METHOTREXATE; MIZORIBINE; N [5 [2 (2 AMINO 1,4,5,6,7,8 HEXAHYDRO 4 OXOPYRIDO[2,3 D]PYRIMIDIN 6 YL)ETHYL] 2 THENOYL]GLUTAMIC ACID; N [[5 [2 (2 AMINO 4,6,7,8 TETRAHYDRO 4 OXO 1H PYRIMIDO[5,4 B][1,4]THIAZIN 6 YL)ETHYL] 2 THIENYL]CARBONYL]GLUTAMIC ACID; NUCLEOTIDE; PEMETREXED; PHOSPHORIBOSYLAMINOIMIDAZOLECARBOXAMIDE FORMYLTRANSFERASE; PIRITREXIM; PURINE NUCLEOTIDE; PYRIMIDINE NUCLEOTIDE; RIBAVIRIN; SELENAZOFURIN; THIOPHENE DERIVATIVE; TIAZOFURIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BIOSYNTHESIS; CHEMISTRY; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; METABOLIC INHIBITION; NUCLEOTIDE METABOLISM; PURINE SYNTHESIS; PYRIMIDINE SYNTHESIS; REACTION ANALYSIS;

ENZYME INHIBITORS; NUCLEOTIDES; PURINE NUCLEOTIDES; PYRIMIDINE NUCLEOTIDES;

EID: 0036851697     PISSN: 00014842     EISSN: None     Source Type: Journal    
DOI: 10.1021/ar0000509     Document Type: Article

References (66)

1. Christopherson, R. I.; Duggleby, R. G. Metabolic resistance: the protection of enzymes against drugs which are tight-binding inhibitors by the accumulation of substrate. Eur. J. Biochem. 1983, 134, 331-335.
2. Bebenek, K.; Roberts, J. D.; Kunkel, T. A. The effects of dNTP pool imbalances on frameshift fidelity during DNA replication. J. Biol. Chem. 1992, 267, 3589-3596.
3. Meyn, R. E.; Stephens, L. C.; Hunter, N. R.; Milas, L. Apoptosis in murine tumors treated with chemotherapy agents. Anticancer Drugs 1995, 6, 443-450.
4. Scheibel, L. W.; Sherman, I. W. In Malaria: Principles and Practice of Malariology; Wernsdorfer, W. H., McGregor, I., Eds.; Churchill Livingston: Melbourne, 1988; Vol. 1, pp 234-242.
5. Grem, J. L.; Daychild, P.; Drake, J.; Geoffroy, F.; Trepel, J. B.; Pirnia, F.; Allegra, C. J. Cytotoxicity and metabolism of 4-methoxy-8-(β-D-ribofuranosylamino)pyrimido[5,4-d]pyrimidine in HCT 116 colon cancer cells. Biochem. Pharmacol. 1994, 48, 2117-2126.
6. Fry, D. W.; Boritzki, T. J.; Jackson, R. C.; Cook, P. D.; Leopold, W. R. Inhibition of 5-phosphoribosyl-1-pyrophosphate synthetase by the monophosphate metabolite of 4-amino-8-(β-D-ribofuranosylamino)pyrimido[5,4-d]pyrimidine: A novel mechanism for antitumor activity. Mol Pharmacol. 1993, 44, 479-485.
7. Schoettle, S. L.; Szabados, M.; Christopherson, R. I. Mechanisms of inhibition of amido phosphoribosyltransferase from mouse L1210 leukemia. Biochemistry 1997, 36, 6377-6383.
8. Sant, M. E.; Lyons, S. D.; Phillips, L.; Christopherson, R. I. Antifolates induce inhibition of amido phosphoribosyltransferase in leukemia cells. J. Biol. Chem. 1992, 267, 11038-11045.
9. Kim, J. H.; Wolle, D.; Haridas, K.; Parry, R. J.; Smith, J. L.; Zalkin, H. A stable carbocyclic analog of 5-phosphoribosyl-1-pyrophosphate to probe the mechanism of catalysis and regulation of glutamine phosphoribosylpyrophosphate amidotransferase. J. Biol. Chem. 1995, 270, 17394-17399.
10. Evans, W. E.; Relling, M. V. Mercaptopurine vs thioguanine for the treatment of acute lymphoblastic leukemia. Leuk. Res. 1994, 18, 811-814.
11. Shi, R. Z.; Lyons, S. D.; Christopherson, R. I. Anticancer mechanisms of thiopurine derivatives against human CCRF-CEM leukaemia cells. Int. J. Biochem. Cell Biol. 1998, 30, 885-895.
12. Habeck, L. L.; Leitner, T. A.; Shackelford, K. A.; Gossett, L. S.; Schultz, R. M.; Andis, S. L.; Shih, C.; Grindey, G. B.; Mendelsohn, L. G. A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyl-transferase and potent activity against solid tumors. Cancer Res. 1994, 54, 1021-1026.
13. Kelley, J. L.; McLean, E. W.; Cohn, N. K.; Edelstein, M. P.; Duch, D. S.; Smith, G. K.; Hanlon, M. H.; Ferone, R. Synthesis and biological activity of an acyclic analogue of 5,6,7,8-tetrahydrofolic acid, N-[4-[[3-(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl) propyl]amino]-benzoyl]-L-glutamic acid. J. Med. Chem. 1990, 33, 561-567.
14. Bissett, D.; McLeod, H. L.; Sheedy, B.; Collier, M.; Pithavala, Y.; Paradiso, L.; Pitsiladis, M.; Cassidy, J. Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034. Br. J. Cancer 2001, 84, 308-312.
15. Peters, G. J.; Ackland, S. P. New antimetabolites in preclinical and clinical development, Exp. Opin. Invest. Drugs 1996, 5, 637-679.
16. Mendelsohn, L. G.; Shih, C.; Schultz, R. M.; Worzalla, J. F. Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol. Invest New Drugs 1996, 14, 287-294.
17. Shih, C.; Chen, V. J.; Gossett, L. S.; Gates, S. B.; MacKellar, W. C.; Habeck, L. L.; Shackelford, K. A.; Mendelsohn, L. G.; Soose, D. J.; Patel, V. F.; Andis, S. L.; Bewley, J. R.; Rayl, E. A.; Moroson, B. A.; Beardsley, G. P.; Kohler, W.; Ratnam, M.; Schultz, R. M. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997, 57, 1116-1123.
18. Antle, V. D.; Liu, D.; McKellars, B. R.; Caperelli, C. A.; Hua, M.; Vince, R. Substrate specificity of glycinamide ribonucleotide transformylase from chicken liver. J. Biol. Chem. 1996, 271, 6045-6049.
19. Moran, R. G.; Baldwin, S. W.; Taylor, E. C.; Shih, C. The 6S- and 6R-diastereomers of 5, 10-dideaza-5, 6, 7, 8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis. J. Biol. Chem. 1989, 264, 21047-21051.
20. Rosowsky, A.; Galivan, J.; Beardsley, G. P.; Bader, H.; O'Connor, B. M.; Russello, O.; Moroson, B. A.; DeYarman, M. T.; Kerwar, S. S.; Freisheim, J. H. Biochemical and biological studies on 2-des-amino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism. Cancer Res. 1992, 52, 2148-2155.
21. Allegra, C. J.; Drake, J. C.; Jolivet, J.; Chabner, B. A. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 4881-4885.
22. Faessel, H. M.; Slocum, H. K.; Jackson, R. C.; Boritzki, T. J.; Rustum, Y. M.; Nair, M. G.; Greco, W. R. Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: The critical role of polyglutamylation. Cancer Res. 1998, 58, 3036-3050.
23. Szabados, E.; Hindmarsh, E.; Phillips, L.; Duggleby, R. G.; Christopherson, R. I. 5-Aminoimidazole-4-carboxamide ribotide transformylase-IMP cyclohydrolase from human CCRF - CEM leukemia cells: Purification, pH dependence and inhibitors. Biochemistry 1994, 33, 14237-14245.
24. Szabados, E.; Manthey, M. K.; Wilson, P. K.; Christopherson, R. I. Inosine-5′-monophosphate analogues as inhibitors of human IMP cyclohydrolase and cellular growth. Biochem. Mol. Biol. Int. 1998, 44, 617-623.
25. Franklin, T. J.; Cook, J. M. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem. J. 1969, 113, 515-524.
26. Sweeney, M. J.; Hoffman, D. H.; Esterman, M. A. Metabolism and biochemistry of mycophenolic acid. Cancer Res. 1972, 32, 1803-1809.
27. Mitchell, B. S.; Dayton, J. S.; Turka, L. A.; Thompson, C. B. IMP dehydrogenase inhibitors as immunomodulators. Ann. N. Y. Acad. Sci. 1993, 685, 217-224.
28. Balzarini, J.; Karlsson, A.; Wang, L.; Bohman, C.; Horska, K.; Votruba, I.; Fridland, A.; Van Aerschot, A.; Herdewijn, P.; De Clercq, E. Eicar (5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis. J. Biol. Chem. 1993, 268, 24591-24598.
29. Yamada, Y.; Natsumeda, Y.; Weber, G. Action of the active metabolites of tiazofurin and ribavirin on purified IMP dehydrogenase. Biochemistry 1988, 27, 2193-2196.
30. Jayaram, H. N.; Ahluwalia, G. S.; Dion, R. L.; Gebeyehu, G.; Marquez, V. E.; Kelley, J. A.; Robins, R. K.; Cooney, D. A.; Johns, D. G. Conversion of 2-β-D-ribofuranosylselenazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties. Biochem. Pharmacol. 1983, 32, 2633-2636.
31. Gharehbaghi, K.; Sreenath, A.; Hao, Z.; Paull, K. D.; Szekeres, T.; Cooney, D. A.; Krohn, K.; Jayaram, H. N. Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin. Biochem. Pharmacol. 1994, 48, 1413-1419.
32. Jain, J.; Almquist, S. J.; Shlyakhter, D.; Harding, M. W. VX-497: A novel, selective IMPDH inhibitor and immunosuppressive agent. J. Pharm. Sci. 2001, 90, 625-637.
33. Collins, K. D.; Stark, G. R. Aspartate transcarbamylase. Interaction with the transition state analogue N-(phosphonacetyl)-L-aspartate. J. Biol. Chem. 1971, 246, 6599-6605.
34. Hoogenraad, N. J. Reaction mechanism of aspartate transcarbamylase from mouse spleen. Arch. Biochem. Biophys. 1974, 161, 76-82.
35. Johnson, R. K.; Swyryd, E. A.; Stark, G. R. Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase. Cancer Res. 1978, 38, 371-378.
36. Grem, J. L.; King, S. A.; O'Dwyer, P. J.; Leyland-Jones, B. Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: A review. Cancer Res. 1988, 48, 4441-4454.
37. Jones, M. E. Pyrimidine nucleotide biosynthesis in animals: Genes, enzymes, and regulation of UMP biosynthesis. Annu. Rev. Biochem. 1980, 49, 253-279.
38. Williams, N. K.; Manthey, M. K.; Hambley, T. W.; O'Donoghue, S. I.; Keegan, M.; Chapman, B. E.; Christopherson, R. I. Catalysis by hamster dihydroorotase: Zinc binding, site-directed mutagenesis, and interaction with inhibitors. Biochemistry 1995, 34, 11344-11352.
39. Christopherson, R. I.; Schmalzl, K. J.; Sharma, S. C. Enzyme Inhibitors. Complete Patent Specification: Australia 77692/87, Japan 220095/87, U.S.A. 091,761, South Africa 87/6552, and Europe 87307744.0, 1987.
40. Christopherson, R. I.; Schmalzl, K. J.; Szabados, E.; Goodridge, R. G.; Harsanyi, M. C.; Sant, M. E.; Algar, E. M.; Anderson, J. E.; Armstrong, A.; Sharma, S. C.; Bubb, W. A.; Lyons, S. D. Mercaptan and dicarboxylate inhibitors of hamster dihydroorotase. Biochemistry 1989, 28, 463-470.
41. Adams, J. L.; Meek, T. D.; Mong, S. M.; Johnson, R. K.; Metcalf, B. W. cis-4-carboxy-6-(mercaptomethyl)-3,4,5,6-tetrahydropyrimidin-2(1H)-one, a potent inhibitor of mammalian dihydroorotase. J. Med. Chem, 1988, 31, 1355-1359.
42. Manthey, M. K.; Huang, D. T. C.; Bubb, W. A.; Christopherson, R. I. Synthesis and enzymic evaluation of 4-mercapto-6-oxo-1,4-azaphosphinane-2-carboxylic acid 4-oxide as an inhibitor of mammalian dihydroorotase. J. Med. Chem. 1998, 41, 4550-4555.
43. Chen, J. J.; Jones, M. E. The cellular location of dihydroorotate dehydrogenase: Relation to de novo biosynthesis of pyrimidines. Arch. Biochem. Biophys. 1976, 176, 82-90.
44. Bennett, L. L., Jr.; Smithers, D.; Rose, L. M.; Adamson, D. J.; Thomas, H. J. Inhibition of synthesis of pyrimidine nucleotides by 2-hydroxy-3-(3,3-dichloroallyl)-1,4-naphthoquinone. Cancer Res. 1979, 39, 4868-4874.
45. Chen, S. F.; Ruben, R. L.; Dexter, D. L. Mechanism of action of the novel anticancer agent 6-fluoro-2-(2′-fluoro-1,1′-biphenyl-4-yl) -3-methyl-4-quinolinecarboxylic acid sodium salt (NSC 368390): Inhibition of de novo pyrimidine nucleotide biosynthesis. Cancer Res. 1986, 46, 5014-5019.
46. Williamson, R. A.; Yea, C. M.; Robson, P. A.; Curnock, A. P.; Gadher, S.; Hambleton, A. B.; Woodward, K.; Bruneau, J. M.; Hambleton, P.; Moss, D.; et al. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J. Biol. Chem. 1995, 270, 22467-22472.
47. Elder, R. T.; Xu, X.; Williams, J. W.; Gong, H.; Finnegan, A.; Chong, A. S. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J. Immunol. 1997, 159, 22-27.
48. Ruckemann, K.; Fairbanks, L. D.; Carrey, E. A.; Hawrylowicz, C. M.; Richards, D. F.; Kirschbaum, B.; Simmonds, H. A. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J. Biol. Chem. 1998, 273, 21682-21691.
49. Mahajan, S.; Ghosh, S.; Sudbeck, E. A.; Zheng, Y.; Downs, S.; Hupke, M.; Uckun, F. M. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFMA13 [α-cyano-β-hydroxy-β-methyl-N-(2, 5-dibromophenyl)propenamide]. J. Biol. Chem. 1999, 274, 9587-9599.
50. Hudson, A. T. Atovaquone - A novel broad-spectrum anti-infective drug. Parasitol. Today 1993, 9, 66-68.
51. Fry, M.; Pudney, M. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl)cyclohexyl]-3-hydroxy1,4-naphthoquinone (566C80). Biochem. Pharmacol 1992, 43, 1545-1553.
52. Seymour, K. K.; Lyons, S. D.; Phillips, L.; Rieckmann, K. H.; Christopherson, R. I. Cytotoxic effects of inhibitors of de novo pyrimidine biosynthesis upon Plasmodium falciparum. Biochemistry 1994, 33, 5268-5274.
53. Seymour, K. K.; Yeo, A. E.; Rieckmann, K. H.; Christopherson, R. I. dCTP levels are maintained in Plasmodium falciparum subjected to pyrimidine deficiency or excess. Ann. Trop. Med. Parasitol. 1997, 91, 603-609.
54. Levine, H. L.; Brody, R. S.; Westheimer, F. H. Inhibition of orotidine-5′-phosphate decarboxylase by 1-(5′-phospho-β-d-ribofuranosyl)barbituric acid, 6-azauridine 5′-phosphate, and uridine 5′-phosphate. Biochemistry 1980, 19, 4993-4999.
55. Chen, J. J.; Jones, M. E. Effect of 6-azauridine on de novo pyrimidine biosynthesis in cultured Ehrlich ascites cells. Orotate inhibition of dihydroorotase and dihydroorotate dehydrogenase. J. Biol. Chem. 1979, 254, 4908-4914.
56. Dix, D. E.; Lehman, C. P.; Jakubowski, A.; Moyer, J. D.; Handschumacher, R. E. Pyrazofurin metabolism, enzyme inhibition, and resistance in L5178Y cells. Cancer Res. 1979, 39, 4485-4490.
57. Cadman, E. C.; Dix, D. E.; Handschumacher, R. E. Clinical, biological, and biochemical effect of pyrazofurin. Cancer Res. 1978, 38, 682-688.
58. Scott, H. V.; Gero, A. M.; O'Sullivan, W. J. In vitro inhibition of Plasmodium falciparum by pyrazofurin, an inhibitor of pyrimidine biosynthesis de novo. Mol. Biochem. Parasitol. 1986, 18, 3-15.
59. Brown, G. K.; O'Sullivan, W. J. Inhibition of human erythrocyte orotidylate decarboxylase. Biochem. Pharmacol. 1977, 26, 1947-1950.
60. McPartland, R. P.; Wang, M. C.; Bloch, A.; Weinfeld, H. Cytidine 5′-triphosphate synthetase as a target for inhibition by the antitumor agent 3-deazauridine. Cancer Res. 1974, 34, 3107-3111.
61. Kang, G. J.; Cooney, D. A.; Moyer, J. D.; Kelley, J. A.; Kim, H. Y.; Marquez, V. E.; Johns, D. G. Cyclopentenylcytosine triphosphate. Formation and inhibition of CTP synthetase. J. Biol. Chem. 1989, 264, 713-718.
62. Yee, L. K.; Allegra, C. J.; Trepel, J. B.; Grem, J. L. Metabolism and RNA incorporation of cyclopentenyl cytosine in human colorectal cancer cells. Biochem. Pharmacol. 1992, 43, 1587-1599.
63. Viola, J. J.; Agbaria, R.; Walbridge, S.; Oshiro, E. M.; Johns, D. G.; Kelley, J. A.; Oldfield, E. H.; Ram, Z. In situ cyclopentenyl cytosine infusion for the treatment of experimental brain tumors. Cancer Res. 1995, 55, 1306-1309.
64. Li, C. M.; Tyler, P. C.; Furneaux, R. H.; Kicska, G.; Xu, Y.; Grubmeyer, C.; Girvin, M. E.; Schramm, V. L. Transition-state analogs as inhibitors of human and malarial hypoxanthine-guanine phosphoribosyltransferases. Nat. Struct. Biol. 1999, 6, 582-587.
65. Wang, F.; Shi, W.; Nieves, E.; Angeletti, R. H.; Schramm, V. L.; Grubmeyer, C. A transition-state analogue reduces protein dynamics in hypoxanthine-guanine phosphoribosyltransferase. Biochemistry 2001, 40, 8043-8054.
66. Takemura, Y.; Jackman, A. L. Folate-based thymidylate synthase inhibitors in cancer chemotherapy. Anticancer Drugs 1997, 8, 3-16.